ERBB2 and glioblastoma: RTK signaling is the most commonly altered pathway in glioblastomas, with genetic alterations occurring in 86% of tumors, including epidermal growth factor receptor (EGFR), erb-B2 receptor tyrosine kinase 2 (ERBB2), and platelet-derived growth factor receptor (PDGFR) (20).